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regulatory reviews faster than the EMA while beginning regulatory review first in 
each case. Three of the four regulatory decisions in which the FDA was slower were 
outliers in terms of approval time. Additionally, when looking at the median, the 
FDA approved these moieties 77 days faster than the EMA while Downing’s findings 
only showed a 44-day differential. This was expected because the analysis included 
the EC decision takes about 2 months on average. ConClusions: After updating 
the data, restricting it to a particular subset of diabetes treatments, and altering 
the EMA regulatory endpoint, Downing et al’s findings not only still hold true, but 
become even more pronounced.
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melliTus (T2Dm) WiTh Very Poor Glycemic conTrol
Schwab P.1, Saundankar V.1, Bouchard J.R.2, Moretz C.1, Baltz J.3
1Comprehensive Health Insights, Louisville, KY, USA, 2Novo Nordisk, Inc., Princeton, NJ, USA, 
3Humana Inc., Louisville, KY, USA
objeCtives: Risk of cardiovascular disease, retinopathy, nephropathy, and neu-
ropathy increases substantially when HbA1c> 7% (suboptimal glycemic control), but 
timely therapy intensification may reduce risk. When HbA1c> 9% (very poor control) 
AACE recommends that triple therapy (asymptomatic patients) or insulin (sympto-
matic patients) be initiated to reach HbA1c≤ 6.5% for patients without concurrent 
illness and at low hypoglycemic risk. Clinical inertia (failure to intensify therapy in 
a timely manner) leads to poor glycemic control. The objective of this study was to 
examine time to treatment modifications in patients with HbA1c≥ 9%. Methods: 
Medical, laboratory, and pharmacy claims data for Humana’s fully insured commer-
cial and Medicare membership were used for this study. Patients with T2DM with 
first HbA1c≥ 9% date (index-date) between Jan 1, 2008–Dec. 31, 2009 were identified. 
Baseline characteristics were obtained within 12 months preceding the index-date. 
Treatment modification was defined as addition or switch of an antidiabetic drug 
class. Study outcome (delay in treatment modification) was assessed as the days 
until modification within the 36-months post-index period. Results: There were 
8,464 patients identified (mean age 66 years, 48% male, 82% from the southern US, 
mean Deyo-Charlson Comorbidity Index 2.54, mean Diabetes Complications Severity 
Index 2.17). Approximately 83% of patients experienced modification within 36 
months; 47% within 90 days of HbA1c≥ 9% index date, 7% between 91-180 days, 5% 
between 181-365 days, while 24% were > 365 days. Around 20% of patients received 
insulin as a modification. Although the proportion of patients receiving triple 
therapy (≥ 3 classes) was still low (23%) at 12 months post-index, it increased from 
10% at baseline. ConClusions: Many patients in poor control receive insufficient 
therapy as recommended by treatment guidelines. Even though additional agents 
were added for some patients, those receiving insulin or triple therapy were low. For 
patients with HbA1c≥ 9%, prompt treatment intensification is needed to improve 
glycemic control and limit complications.
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objeCtives: This study examined different types of medical costs associated with 
early discontinuation (ED) of insulin therapy and with restarting of insulin among 
ED patients in the treatment of type 2 diabetes mellitus (T2DM). Methods: Truven’s 
Health Analytics Commercial Claims and Encounters database from 1/1/08 through 
12/31/11 were utilized. ED was defined as discontinuation of insulin therapy for at 
least 30 days in the first 90 days post initiation. Generalized linear models with log-
link were used to examine the association between ED and total medical costs, acute 
care (hospitalization and emergency room) costs, outpatient costs, diabetes-related 
drug costs and all-cause drug costs. Among ED patients, the association between 
restarting insulin therapy and costs were also examined. Analyses controlled for 
patient characteristics, index medication prescribed, patient general health, comor-
bidities, prior resource utilization, and prior medication utilization. Results: Most 
(82% of 74,399) individuals discontinued insulin therapy in the first year post initia-
tion and 75% of these patients were ED. Compared to non-ED, ED was associated 
with 9.6% higher acute care costs (P= 0.0003), while outpatient costs, diabetes-related 
drug costs, all-cause drug costs and total medical costs were all significantly lower 
among ED patients. Among the ED cohort, 90% restarted therapy over the post-
period, with 53% restarting within 4 months. Compared to non-restart, the restart of 
insulin therapy after ED was associated with 11.3% higher acute care costs (P= 0.033), 
24.0% higher outpatient costs (P< 0.001), 80.2% higher all-cause drug costs (P< 0.001, 
and 30.3% higher total medical costs (P< 0.001). ConClusions: Current findings 
suggest that during the first three months following initiation of insulin therapy 
for T2DM, the ED of insulin therapy and its restart are associated with higher acute 
care costs. Such costs are often considered avoidable or modifiable costs and tend 
to signal poorer long-term treatment outcomes.
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objeCtives: To compare recent trends in treatment pattern for diabetes between 
2002 and 2010. Methods: A cross-sectional study of expenditures was carried 
for representative sample of civilian, noninstitutionalized U.S individuals with 
diabetes from the Medical Expenditure (MEPS) 2002-2010. Expenditures include 
all sources of payment for oral anti-diabetic medications, insulin, and non-insulin 
injectables. We inflated 2002 dollar values to 2010 values using the consumer price 
index. Results: From 2002 to 2010, the estimated number of persons reporting 
as pellets was higher than those with other formulations. Patients starting with a 
patch demonstrated the highest switching rate compared to other formulations.
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objeCtives: DPP-4 inhibitors produce a modest improvement in HgbA1C with 
relatively few adverse effects. Little is known about the characteristics and treat-
ment patterns of patients receiving DPP-4 inhibitors in the US. The objectives of 
the current study were to characterize patients prescribed DPP-4 inhibitors and 
examine patterns of anti-diabetic medication use in the one year following their 
initiation. Methods: Data were obtained from Humedica’s National Electronic 
Health Record-Derived Longitudinal Patient-Level Database (2007–2011). The study 
cohort included all adult patients with T2DM who received a first prescription for a 
DPP-4 inhibitor during the study period and who had at least one HgbA1C value at 
baseline. Baseline patient demographics, clinical characteristics and anti-diabetic 
medication use in the one-year follow-up period were assessed. Cox proportional 
hazard models were used to assess independent predictors of the aggregate out-
come of switching or augmentation. Results: Of the 8700 patients in the study 
cohort, 84% were older than 50, and 52% were female; the mean BMI was 34.4 and 
mean HgbA1c at baseline was 7.81%. Overall, 2226 (25.6%) patients switched or 
augmented therapy within the first year following DPP-4 inhibitor initiation after 
a mean of 6.1 months; the most frequently observed patterns included a switch 
to another oral agent (n= 1791, 20.6%) or to insulin (n= 306, 3.5%). Higher baseline 
HgbA1C (HR 1.20 [95% CI 1.14-1.26] for HgbA1C > 9% vs. < 7%) and higher BMI (HR 
1.11 [95% CI 1.06-1.16] for BMI ≥ 30 vs. 25-29) predicted higher rates of switching/
augmentation, while female gender (HR 0.92 [95% CI 0.89-0.95]) and younger age 0.42 
[95% CI 0.22-0.81]) predicted lower rates. ConClusions: In this US cohort, change 
in anti-diabetic treatment was relatively uncommon in the one year following ini-
tiation of a DPP-4 inhibitor. Baseline characteristics including HgbA1C, BMI and 
demographics can be used to inform the likelihood of switching or augmentation.
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objeCtives: Centers for Medicare and Medicaid Services (CMS) assess the per-
formance of health insurance plans using quality of care measures. This study 
assessed achievement of 8 diabetes-related quality measures at the patient 
level and examined whether achievement was associated with fewer complica-
tions. Methods: Claims and member-level quality data between January 2010 
and December 2011 were obtained from a Medicare Advantage Prescription Drug 
Insurance provider. Patients with type 1 or type 2 diabetes on the index date 
(January 1, 2011) and with 12 months of pre- and post-index continuous enroll-
ment were included. Quality of care and diabetes complications were assessed 
during the post-index year. The impact of quality metric achievement on new or 
worsening diabetes complications was assessed with a logistic regression model, 
which adjusted for baseline characteristics. Results: Cohort size ranged from 
159,454 to 4,464, depending on the quality measure and patient-level data avail-
ability. Most patients (> 80%) achieved LDL-C screening, nephropathy assessment, 
and medication adherence standards. Over 99% of patients met dosing standards 
for biguanides, sulfonylureas, and thiazolidinediones. Eye screening and use of 
appropriate anti-hypertensive treatments had lower achievement levels (50.3% 
and 54.2%, respectively). A majority (61%) of patients achieved HbA1c< 9%; 29% of 
patients achieved LDL-C control < 100mg/dl. Logistic regression estimates showed 
that failure to reduce HbA1c below 9% statistically significantly increased the 
risk of new or worsening diabetes complications [(OR, 1.12 (95% CI, 1.10-1.15); 
p< 0.0001)] as did failure to use anti-hypertensive treatment [(OR, 1.40, (95% CI, 
1.24-1.59); p< 0.0001]. ConClusions: Data from a 1-year observation period sug-
gests that attainment of CMS diabetes quality metrics was associated with lower 
new or worsening complication risk. Since the full impact of improved care may 
not be properly assessed within such a short time, follow-up longitudinal studies 
would shed light on the long-term impact of achieving quality measures.
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objeCtives: In 2012, Downing et al published a novel study in the NEJM that com-
pared the speed of regulatory agencies between 2001-2010, which demonstrated the 
FDA’s relative quickness. This paper narrows the scope to new non-insulin depend-
ent type II diabetes drugs approved by the EMA and FDA (using their respective 
websites) during 2005-2013, accounting for new drug approvals and legal updates 
to regulatory systems in a disease condition that has faced a plethora of regu-
latory challenges. Methods: Unlike Downing, this study looks at the European 
Commission’s (EC) decision, instead of the Committee for Medical Products for 
Human Use’s (CHMP) recommendation. A Marketing Authorization is issued upon 
EC decision, making it analogous with the data captured surrounding the FDA’s 
approval process. Additionally this analysis looks at the date submitted to the FDA 
and EMA as well as the approval date. The data consists of 12 non-insulin dependent 
moieties approved between 2005 and 2013. Results: Out of the 12 new treatments, 
10 were approved first by the FDA (83%). Additionally, the FDA began reviews before 
the EMA with a median time of 126.5 days. The FDA also completed 8 of the 12 
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objeCtives: To identify factors associated with failure of telaprevir- and boceprevir-
based HCV triple therapy at a tertiary referral center in New York. Methods: 
Records of 223 patients with genotype 1 HCV mono-infection who initiated triple 
therapy with peg-IFN/RBV plus telaprevir or boceprevir between 5/2011 and 3/2012 
were reviewed. Data were analyzed on an intention-to-treat basis by multivari-
able logistic regression and classification and regression tree models. Results: 
Overall, 172 patients were on telaprevir and 51 were on boceprevir. Median age 
was 57 years, 35% were female, 18% were black, 44% had F3-F4 fibrosis (Fib-4 ≥ 
3.25), 31% were naïve to treatment, 53% had genotype 1a, and 9% of those tested 
had IL28B CC genotype. Overall, 48% completed the expected course of therapy. 
Treatment failure (58% of patients) was associated with insufficient viral suppres-
sion or breakthrough (30%), adverse events (14%), relapse (12%), and loss to follow 
up (2%). Black race increased the risk of failure (OR: 5.92; 95% CI: 2.34-14.96), whereas 
HCV genotype 1b (OR:0.36; 95% CI: 0.18-0.69), higher platelets (OR: 0.91 per 10x103/
µL; 95% CI: 0.86-0.96), and IL28B CC genotype (OR: 0.28; 95% CI: 0.10-0.84) decreased 
the risk. In a classification tree, platelets < 137 x 103/µL were the strongest predictor 
of non-SVR24. The absence of HCV RNA at week 4 (telaprevir) or week 8 (boceprevir) 
were the only on-treatment variables independently (and inversely) related to non-
SVR. ConClusions: Low platelets were an important negative predictor, suggest-
ing that treatment may be more effective if initiated before the onset of advanced 
liver disease and thrombocytopenia.(NIDA031095,NIDDK090317,Janssen)
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objeCtives: Three PCVs (7-, 10-, and 13-valent) have been launched in Taiwan; 
only PCV10 and PCV13 are available in the current market. The City immunization 
program (CIP) in New Taipei City (NTC) started offering one dose of PCV in 2007 for 
children aged 2-5. PCV7 was provided initially and switched to PCV13 in 2012. To 
date, there is no research on the effectiveness of PCVs in Taiwan. This study evalu-
ated the real-world impact of PCVs on invasive pneumococcal disease (IPD) in NTC, 
the largest population city in Taiwan. Methods: Data were derived from National 
Immunization Information System and National IPD Reporting System. Descriptive 
analysis was applied to summarize the vaccination trend and characteristics of 
IPD cases. The risk of IPD from vaccine-covered serotypes with PCV was estimated 
using incidence rate ratio (IRR), and the vaccine effectiveness was calculated as 
1- IRR. Vaccinated was defined as children who had at least one dose of PCV. If 
multiple PCVs were used, children were assigned to the PCV with more covered 
serotypes. Results: Total of 321,631 children born in NTC between Jan 1st, 2004 
and June 30th, 2013 were included. There were 183,342 children (58%) vaccinated; 
among these 46.0%, 51.7%, and 1.4% with PCV7, PCV13, PCV10, respectively. PCV10 
was excluded for the risk analysis, due to low utilization. Among 152 identified 
IPD cases, 84 cases (55.3%) were caused by serotype 19A. Most events occurred in 
children 3 (21.7%) and 2 (21.1%) years of age. The adjusted IRR of IPD (PCV-7 covered 
serotypes) for PCV7 was 0.29 (p= 0.012); VE 71%. The adjusted IRR of IPD for PCV13 
(PCV-13 covered serotypes) was 0.2 (p= 0.001); VE 80%. ConClusions: Due to the 
CIP, over half of children 5 years and younger received a PCV in NTC. PCV vaccination 
significantly reduced the risk of IPD.
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objeCtives: Influenza burden might be reduced by replacing current trivalent 
influenza vaccines (TIV, containing one B lineage) with quadrivalent vaccines 
(QIV, containing both Yamagata and Victoria influenza B lineages). This study 
(ClinicalTrials.gov: NCT01599390) assessed the potential added benefit of QIV 
versus TIV use on the prevention of influenza-attributable hospitalizations and 
deaths in the United States during 12 influenza seasons (July 1997–April 2009) 
as a consequence of preventing influenza B lineage mismatch. Methods: 
Hospitalization and mortality data from the Nationwide Inpatient Sample and 
National Vital Statistics System databases, respectively, were used to quantify the 
influenza-attributable burden through virus-guided regression models. Based on 
Reed’s probability model (Reed et al, Vaccine 2012;30:1993-8), a simple multiplier 
model was developed to estimate the “respiratory disease broadly defined” (RDBD) 
outcome rates had B lineage mismatch seasons been avoided. Hospitalizations 
with primary, and deaths with any mention of RDBD diagnostic codes (respiratory 
disease, cough, abnormalities of breathing, fever or viral infections not other-
wise specified) were considered influenza-attributable. The model used avail-
able vaccine coverage data (primary source: CDC Morbidity & Mortality Weekly 
Reports; secondary sources: National Health Interview Survey reports, National 
Immunization Survey, Behavioral Risk Factor Surveillance System) and vaccine 
effectiveness values from the literature. Results: The highest numbers of QIV-
preventable hospitalizations and deaths were attributed to ≥ 75-year-olds: 3,141 
and 461 on average per season, respectively. During the worst mismatched season 
(2007/2008), across all ages, 41% and 28% of influenza-attributable hospitalizations 
medication therapy for diabetes increased from 11.8 to 17.6 million, but the per-
centage of patients receiving prescription medication for diabetes dropped from 
90.5% to 87.5% (p< .001). The mean number of physician’s office visits for treating 
diabetes increased from 45.9 million in 2002 to 55.9 million in 2010, while the 
mean number of visits per treated patient declined from 4.7 to 3.9 during the 
same period. Among the patients used prescription medications, the proportion of 
those using both insulin and oral anti-diabetic medications increased from 14.9% 
in 2002 to 18.4% in 2010. For specific classes of oral anti-diabetic medications, the 
percentage using biguanides increased from 40.1% to 60.5%, in the contrast, use 
of sulfonylureas and thiazolidinediones dropped from 50.1% to 36.1% and 20.7% to 
12.8% respectively. The annual expenditures per user for medications for treating 
diabetes increased from $889 in 2002 to $1026 in 2010. Increasing use of newer 
insulin and thiazoliones was the main driver of recent increases in the medica-
tion expenditures ($10.5 billion in 2002 to $18.1 billion in 2007). ConClusions: 
Increasing costly medication therapy for diabetes is being applied to an increasing 
population. However, the percentage of diabetes patients received medication 
treatment slightly dropped. This suggests that much more attention should be 
directed in reducing the gap between treatment need and use as well as evaluation 
of more costly medication therapy for diabetes.
infecTion – clinical outcomes studies
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objeCtives: Anaphylaxis is a serious allergic reaction that has been reported as a 
rare adverse drug reaction (ADR) in cephalosporin antibiotics, predominantly cef-
triaxone, causing several deaths. We aimed to evaluate reports of anaphylaxis with 
3rd generation cephalosporins (ATC code= J01DD) using a disproportionality analysis 
of spontaneous adverse event reports. Methods: Our case-control study identified 
anaphylaxis (cases) or other adverse events (controls) in FAERS from January 2004 to 
September 2012 for 3rd generation cephalosporin antibiotics. Reporting odds ratio 
(ROR) and proportional reporting ratio (PRR) were calculated to estimate risk for 
each 3rd generation cephalosporin. Only primary suspected drugs and initial status 
of reports were studied. Results: Of 9315 eligible ADR reports for 3rd generation 
cephalosporins, 278 (3%) anaphylaxis ADRs were reported, with 100 (36%) deaths, 
68 (25%) hospitalizations, and 52 (19%) life-threatening events. Ceftriaxone was the 
most commonly reported cephalosporin exposure among anaphylaxis cases (n= 189, 
67.9%). Of the anaphylaxis cases associated with ceftriaxone, death was reported in 
43%, hospitalization in 24%, and life-threatening events in 21% of cases. The odds 
of exposure was significantly higher with cefoperazone (ROR 3.88, 95% confidence 
interval [CI] 2.71-5.56) and ceftriaxone (ROR= 1.92, CI= 1.49-2.48) and significantly 
lower with cefdinir (ROR= 0.15, CI= 0.08-0.29) and cefotaxime (ROR= 0.31, CI= 0.12-
0.84) among cases compared to controls. Similarly, PRR indicated a significantly 
increased risk of anaphylaxis with cefoperazone (PRR= 3.60, CI= 2.60-5.00) and cef-
triaxone (PRR= 1.89, CI= 1.47-2.42) and a significantly decreased risk with cefdinir 
(PRR= 0.16, CI= 0.08-0.29) and cefotaxime (PRR= 0.32, CI= 0.12-0.85) as compared to 
controls experiencing non-anaphylaxis adverse events. Both ROR and PRR were non-
significant for cefditoren, cefpodoxime, ceftazidime and ceftibuten. ConClusions: 
Among 3rd generation cephalosporins, which are commonly used to treat bacte-
rial infections, patients having anaphylaxis ADRs were found to have significantly 
higher odds of cefoperazone and ceftriaxone exposure, but significantly lower odds 
of cefdinir and cefotaxime exposure compared to patients having other ADRs.
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objeCtives: The objective of this study was to describe the antibiotic treatment 
patterns among patients with newly-diagnosed Lyme disease (LD). Some published 
treatment guidelines specify short-course antibiotic treatment for early LD lasting 
10-28 days, but there are conflicting recommendations. Little is known about real-
world LD treatment patterns. Methods: Patients newly diagnosed with LD (ICD-9: 
088.81) in 2010-2012 were identified in the Truven Health MarketScan® Commercial 
and Medicare Supplemental Databases. Continuous enrollment was required one 
year pre- and three months post-LD diagnosis. Patients were excluded if they used 
antibiotics in the prior 90 days or had another infection diagnosis in the week 
prior to or following the index LD diagnosis. Outcomes were the portion of patients 
receiving antibiotics within 14 days post-LD diagnosis, as well as duration and 
types of antibiotics received. Results: A total of 10,783 patients met the selec-
tion criteria (mean age 42.0 years [SD= 20.6]; 44% female). Of these patients, 64% 
initiated antibiotic therapy within 14 days of their index LD diagnosis. On average, 
patients used antibiotics for 28.3 (SD= 27.4, median= 21.0) days following a new LD 
diagnosis. The majority of patients (78.3%) were treated with antibiotics for 10-30 
days; relatively few patients (3%) were treated for less than 10 days. A substan-
tial portion (18.7%) were treated with antibiotics for more than one month, with 
some treated for more than two (5.3%) or three months (2.9%). Newly-diagnosed LD 
patients were treated primarily with types of antibiotics mentioned in published 
treatment guidelines (doxycycline [73%], amoxicillin [22%], cefuroxime [4%]), with 
very little use of antibiotics deviating from guidelines (e.g., azithromycin [3%] and 
ciprofloxacin [1%]). ConClusions: Optimal treatment for newly-diagnosed LD 
remains undefined. Results of this study substantiate anecdotal evidence that a 
substantial portion of LD patients are being treated with antibiotics for longer than 
advocated in published guidelines or not at all.
